Literature DB >> 25228559

Aplastic anemia in adolescents and young adults.

Amy E DeZern1, Eva C Guinan.   

Abstract

Adolescent and young adult patient presentations of aplastic anemia require a particular perspective on both diagnosis and treatment. This unique age group necessitates a thorough diagnostic evaluation to ensure the etiology, acquired or inherited, is sufficiently determined. The treatment options include human leukocyte antigen-identical sibling hematopoietic cell transplantation or immunosuppressive therapy, and both require attention to the specific medical and social needs of these adolescents and young adults. Longitudinal surveillance throughout life for the development of late complications of the disease and treatment is mandatory.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25228559      PMCID: PMC4183226          DOI: 10.1159/000360209

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  42 in total

1.  Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  Gerard Socie; Jean-Yves Mary; Hubert Schrezenmeier; Judith Marsh; Andrea Bacigalupo; Anna Locasciulli; Monica Fuehrer; Albert Bekassy; Andre Tichelli; Jakob Passweg
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 2.  ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis.

Authors:  Anat Gafter-Gvili; Ron Ram; Ronit Gurion; Mical Paul; Moshe Yeshurun; Pia Raanani; Ofer Shpilberg
Journal:  Acta Haematol       Date:  2009-02-25       Impact factor: 2.195

3.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

Authors:  Chiharu Sugimori; Tatsuya Chuhjo; Xingmin Feng; Hirohito Yamazaki; Akiyoshi Takami; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

4.  Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.

Authors:  Phillip Scheinberg; Olga Nunez; Colin Wu; Neal S Young
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

5.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

Authors:  Hubert Schrezenmeier; Jakob R Passweg; Judith C W Marsh; Andrea Bacigalupo; Christopher N Bredeson; Eduardo Bullorsky; Bruce M Camitta; Richard E Champlin; Robert Peter Gale; Monika Fuhrer; John P Klein; Anna Locasciulli; Rosi Oneto; Antonius V M B Schattenberg; Gerard Socie; Mary Eapen
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

6.  Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children.

Authors:  Abdulrahman Alsultan; Neil A Goldenberg; Nicole Kaiser; Douglas K Graham; Taru Hays
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

7.  Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.

Authors:  Mark Lawler; Shaun R McCann; Judith C W Marsh; Per Ljungman; Jill Hows; Elisabeth Vandenberghe; Joan O'Riordan; Anna Locasciulli; Gérard Socié; Alan Kelly; Hubert Schrezenmeier; Pedro Marin; André Tichelli; Jakob R Passweg; Anne Dickenson; Jacqueline Ryan; Andrea Bacigalupo
Journal:  Br J Haematol       Date:  2009-01-09       Impact factor: 6.998

8.  Hematopoietic stem cell transplantation in patients with active fungal infection: not a contraindication for transplantation.

Authors:  Z S Aki; G T Sucak; Z A Yeğin; O Güzel; G Erbaş; E Senol
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

Review 9.  Diagnosis, genetics, and management of inherited bone marrow failure syndromes.

Authors:  Blanche P Alter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

Review 10.  Hematopoietic growth factors in the treatment of acquired bone marrow failure states.

Authors:  Judith C W Marsh; Arnold Ganser; Michael Stadler
Journal:  Semin Hematol       Date:  2007-07       Impact factor: 3.851

View more
  4 in total

1.  Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.

Authors:  Amy E DeZern; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2018-07-26       Impact factor: 5.742

2.  Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study.

Authors:  Xiao-Fan Zhu; Hai-Long He; Shun-Qing Wang; Jing-Yan Tang; Bing Han; Dong-Hua Zhang; Li-Qiang Wu; De-Pei Wu; Wei Li; Ling-Hui Xia; Huan-Ling Zhu; Feng Liu; Hong-Xia Shi; Xi Zhang; Fang Zhou; Jian-Da Hu; Jian-Pei Fang; Xie-Qun Chen; Tie-Zhen Ye; Ying-Min Liang; Jie Jin; Feng-Kui Zhang
Journal:  Acta Haematol       Date:  2019-05-15       Impact factor: 2.195

3.  Umbilical cord blood transplantation supplemented with the infusion of mesenchymal stem cell for an adolescent patient with severe aplastic anemia: a case report and review of literature.

Authors:  Chengxin Luan; Runzhe Chen; Baoan Chen; Jiahua Ding; Ming Ni
Journal:  Patient Prefer Adherence       Date:  2015-06-11       Impact factor: 2.711

4.  Pancytopenia of Unknown Cause in Adult Patients Admitted to a Tertiary Hospital in Ethiopia: Case series.

Authors:  Esayas Kebede Gudina; Hiwot Amare; Kasahun Benti; Shoba Ibrahim; Gashahun Mekonnen
Journal:  Ethiop J Health Sci       Date:  2018-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.